An Ultra‐Fast UPLC‐MS/MS Method for Quantifying Ivosidenib: Application to Assessment of Metabolic Stability in Human Liver Microsomes
Ivosidenib (Tibsovo) is a groundbreaking, first‐in‐class medication that specifically and reversibly blocks isocitrate dehydrogenase (IDH1), earning multiple FDA approvals for cancers harboring IDH1 mutations. This research developed a rapid, dependable, and sensitive UPLC‐MS/MS technique to assess the metabolic stabil...